Teva Pharmaceutical Industries (TEVA) Cash from Investing Activities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Cash from Investing Activities for 18 consecutive years, with $229.0 million the latest figure, recorded in Q1 2026.

• Quarterly Cash from Investing Activities rose 13.93% year-over-year to $229.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $765.0 million (down 9.89% YoY) and the FY2025 annual result came in at $737.0 million, down 6.94% from the prior year.
• Cash from Investing Activities climbed to $229.0 million in Q1 2026 per TEVA's latest filing, from $165.0 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for TEVA reached as high as $302.0 million in Q2 2023 and fell as low as $135.0 million in Q3 2025.
• A 5-year average of $198.9 million and a median of $181.0 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 68.31% — and 2023, when it jumped 79.17%.
• Year by year, Cash from Investing Activities stood at $168.0 million in 2022, then soared by 79.17% to $301.0 million in 2023, then plunged by 32.89% to $202.0 million in 2024, then declined by 18.32% to $165.0 million in 2025, then soared by 38.79% to $229.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $229.0 million, $165.0 million, and $135.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.